☰

Amanda C. Winters, Ph.D. - Publications

Affiliations: 
2011 Biomedical Sciences Tulane University, New Orleans, LA, United States 
Area:
Cell Biology, Oncology
Tree Info Similar researchers PubMed Report error

27 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Murphy LA, Winters AC. Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells. Biomedicines. 11. PMID 38137469 DOI: 10.3390/biomedicines11123248  0.364
2023 Winters AC, Minhajuddin M, Stevens BM, Major A, Bosma G, Abbott D, Miltgen N, Yuan J, Treece AL, Siegele BJ, Ewalt MD, Gutman JA, Jordan CT, Pollyea DA. Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine. Haematologica. PMID 38105738 DOI: 10.3324/haematol.2023.283790  0.316
2022 Winters AC, Bosma G, Abbott D, Minhajuddin M, Jordan C, Pollyea DA, Gutman JA. Outcomes Are Similar Following Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy. Transplantation and Cellular Therapy. PMID 35902048 DOI: 10.1016/j.jtct.2022.07.022  0.303
2020 Stevens BM, Jones CL, Pollyea DA, Culp-Hill R, D'Alessandro A, Winters A, Krug A, Abbott D, Goosman M, Pei S, Ye H, Gillen AE, Becker MW, Savona MR, Smith C, et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nature Cancer. 1: 1176-1187. PMID 33884374 DOI: 10.1038/s43018-020-00126-z  0.328
2020 Jones CL, Stevens BM, Pollyea DA, Culp-Hill R, Reisz JA, Nemkov T, Gehrke S, Gamboni F, Krug A, Winters A, Pei S, Gustafson A, Ye H, Inguva A, Amaya M, et al. Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. Cell Stem Cell. PMID 32822582 DOI: 10.1016/J.Stem.2020.07.021  0.345
2020 Winters AC, Maloney KW, Treece AL, Gore L, Franklin AK. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia. Pediatric Blood & Cancer. e28398. PMID 32735397 DOI: 10.1002/Pbc.28398  0.401
2020 Winters AC, Maloney KW, Treece AL, Gore L, Franklin AK. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia. Pediatric Blood & Cancer. e28398. PMID 32735397 DOI: 10.1002/pbc.28398  0.304
2020 Winters AC, Maloney KW, Treece AL, Gore L, Franklin AK. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia. Pediatric Blood & Cancer. e28398. PMID 32735397 DOI: 10.1002/pbc.28398  0.304
2020 Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, et al. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients. Cancer Discovery. PMID 31974170 DOI: 10.1158/2159-8290.Cd-19-0710  0.43
2019 Winters A, Gore L. Moving immunotherapy into the front line in ALL. Hematology. American Society of Hematology. Education Program. 2019: 209-217. PMID 31808875 DOI: 10.1182/Hematology.2019000017  0.422
2019 Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, Schowinsky JT, Rosser J, Ewalt MD, Siegele B, Rana V, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Advances. 3: 2911-2919. PMID 31648312 DOI: 10.1182/Bloodadvances.2019000243  0.377
2019 Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. CD123 CAR T Cells for the Treatment of Myelodysplastic Syndrome. Experimental Hematology. PMID 31136781 DOI: 10.1016/J.Exphem.2019.05.002  0.387
2019 Stevens B, Winters A, Gutman JA, Fullerton A, Hemenway G, Schatz D, Miltgen N, Wei Q, Abbasi T, Vali S, Singh NK, Drusbosky L, Cogle CR, Hammes A, Abbott D, et al. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. Leukemia Research. 81: 43-49. PMID 31009835 DOI: 10.1016/J.Leukres.2019.04.005  0.39
2019 Pei S, Pollyea DA, Gustafson A, Minhajuddin M, Stevens BM, Ye H, Inguva A, Amaya ML, Krug A, Jones CL, Adane B, Winters A, Khan N, Ponder J, Schowinsky J, et al. Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy Blood. 134: 185-185. DOI: 10.1182/Blood-2019-131390  0.424
2019 Gutman JA, Sharma P, Purev E, Smith C, Winters A, Hammes A, Loken MR, Pollyea DA. Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy Blood. 134: 4615-4615. DOI: 10.1182/Blood-2019-129150  0.384
2019 Winters A, Gutman JA, Purev E, Stevens BM, Pei S, Schowinsky J, Abbott D, Hammes A, Nakic M, Lyle L, Halsema K, Macero D, Hirose A, Boggs C, Falco A, et al. Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy Blood. 134: 2638-2638. DOI: 10.1182/Blood-2019-122120  0.335
2018 Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, D'Alessandro A, Culp-Hill R, Riemondy KA, Gillen AE, Hesselberth JR, Abbott D, Schatz D, Gutman JA, Purev E, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nature Medicine. PMID 30420752 DOI: 10.1038/S41591-018-0233-1  0.476
2018 Ye H, Adane B, Khan N, Alexeev E, Nusbacher N, Minhajuddin M, Stevens BM, Winters AC, Lin X, Ashton JM, Purev E, Xing L, Pollyea DA, Lozupone CA, Serkova NJ, et al. Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells. Cancer Cell. PMID 30270124 DOI: 10.1016/J.Ccell.2018.08.016  0.313
2018 Stevens BM, Khan N, D'Alessandro A, Nemkov T, Winters A, Jones CL, Zhang W, Pollyea DA, Jordan CT. Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes. Nature Communications. 9: 3694. PMID 30209285 DOI: 10.1038/S41467-018-05984-X  0.425
2018 Stevens BM, Jones CL, Winters A, Dugan J, Abbott D, Savona MR, Fesik SW, Pollyea DA, Jordan CT. PTPN11 Mutations Confer Unique Metabolic Properties and Increase Resistance to Venetoclax and Azacitidine in Acute Myelogenous Leukemia Blood. 132: 909-909. DOI: 10.1182/Blood-2018-99-119806  0.397
2018 Stevens BM, Winters A, Abbasi T, Singh NK, Ullal YS, Kumari I, Tyagi A, Alam A, Lunkad N, Drusbosky LM, Cogle CR, Vali S, Pollyea DA. WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML) Blood. 132: 1538-1538. DOI: 10.1182/Blood-2018-99-114429  0.4
2018 Winters A, Goosman M, Stevens BM, Purev E, Smith C, Pollyea DA, Jordan CT, Gutman JA. Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant Blood. 132: 2138-2138. DOI: 10.1182/Blood-2018-99-110834  0.389
2017 Winters AC, Bernt KM. MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. Frontiers in Pediatrics. 5: 4. PMID 28232907 DOI: 10.3389/Fped.2017.00004  0.46
2017 Pollyea DA, Stevens BM, Winters A, Minhajuddin M, Gutman JA, Purev E, Smith C, Abbott D, Jordan CT. Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies Blood. 130: 181-181. DOI: 10.1182/Blood.V130.Suppl_1.181.181  0.407
2017 Stevens BM, Winters A, Gutman JA, Fullerton A, Hemenway G, Miltgen N, Wei Q, Abbasi T, Vali S, Singh NK, Drusbosky LM, Cogle CR, Hammes A, Jordan CT, Pollyea DA. Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics Blood. 130: 1337-1337. DOI: 10.1182/Blood.V130.Suppl_1.1337.1337  0.33
2009 Bennett CA, Winters AC, Barretto NN, Hemenway CS. Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents Leukemia Research. 33: 937-947. PMID 19232721 DOI: 10.1016/J.Leukres.2009.01.018  0.624
2008 Palermo CM, Bennett CA, Winters AC, Hemenway CS. The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells Leukemia Research. 32: 633-642. PMID 17875318 DOI: 10.1016/J.Leukres.2007.08.002  0.622
Show low-probability matches.